Kolexia
Tazi Youssef Oncologie médicale
Tazi Youssef
Oncologie médicale
Clinique Saint-luc
Schirmeck, France
111 Activités
1.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs de la prostate Tumeurs du sein Carcinome épithélial de l'ovaire Carcinomes Tumeurs prostatiques résistantes à la castration Carcinome épidermoïde Fatigue Tumeurs de l'utérus

Collaborateurs

Voir plus
Pautier Patricia
Pautier Patricia
Gustave-Roussy, Villejuif, France
Lhomme Catherine
Lhomme Catherine
Gustave-Roussy, Villejuif, France
Bompas Emmanuelle
Bompas Emmanuelle
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Leary Alexandra
Leary Alexandra
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Clovis Oncology
5 collaboration(s)
Dernière en 2022
Ipsen
2 collaboration(s)
Dernière en 2021
Daiichi Sankyo
2 collaboration(s)
Dernière en 2022
MSD
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023
Efficacité de la prise en charge nutritionnelle : étude prospective sur 6 mois, au sein d’une cohorte de 66 patients dénutris
86e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 juin 2023
PEACE2: A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Essai Clinique (Sanofi)   28 octobre 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
European journal of cancer (Oxford, England : 1990)   05 septembre 2022
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
Essai Clinique (Arcagy Research)   01 août 2022
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (Jiangsu HengRui Medicine Co., Ltd.)   28 juillet 2022
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
European urology   14 novembre 2021
Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.
Cancers   15 juillet 2021
COVID-19 in Patients with Cancer: A Retrospective Study of 212 Cases from a French SARS-CoV-2 Cluster During the First Wave of the COVID-19 Pandemic.
The oncologist   03 juin 2021